Sentences with phrase «results for patients»

Acceptance and Commitment Therapy for Anxiety Disorders: A Practitioner's Treatment Guide to Using Mindfulness, Acceptance, and Values - Based Behavior Change Strategies by Georg H. Eifert, John P. Forsyth, and Steven C. Hayes is an excellent resource for transferring your interest in ACT into real results for your patients.

Interfaces with traditional and alternative health practitioners to get best results for patients.

The DePuy ASR Hip Implant Recall - Defective Design Leads to Disastrous Results for Patients, Florida Justice Association Journal, Issue 549, November / December, 2010

Botton line; doctors will have blood test results for their patients in 1 - 2 hours, instead of the 2 - 3 days it currently takes.

This all adds up to predictably remarkable results for your patients and immediate economic impact for your practice.

We strongly believe that the most successful results for our patients are the product of a team effort among the pet's family, veterinarian, animal rehabilitation professional and our My Pet's Brace practitioners.

She is uniquely situated to finally bridge the gap between the research and patient care arenas, for she possesses the necessary vision to translate the latest information available into life - altering results for her patients.

Since exercise does not impact the benefits provided by prescription medications for depression, many researchers are interested in determining how the two treatment options could partner together to produce even better overall results for patients.

For example, she has seen dramatic results for patients with type 2 diabetes, high cholesterol and high blood pressure who go on a whole - food, plant - based diet.

«The results for the patients it helps are absolutely spectacular, but those patients are only a sliver of the population with the disease,» says Munos.

The group will review the relevant imaging and other test results for patients who will be seen in the clinic.

«Our algorithm allows us to be much smarter about whom we operate on up front, providing a more individualized approach to surgery that's led to better results for our patients,» said Anil Sood, M.D., professor of Gynecologic Oncology and Reproductive Medicine and senior author of the paper.

«Similarly 71 drugs approved by the FDA from 2002 to 2014 for solid tumours have resulted in median gains in progression - free and overall survival of only 2.5 and 2.1 months, respectively,» he says adding, «Also, only 42 per cent met the American Society of Clinical Oncology Cancer Research Committee's criteria for meaningful results for patients.»

We have to fund innovations, we have to seed new ways of doing things and we have to get them in place so we can get the money out of the system that is being spent unnecessarily today without getting good results for patients and is causing more complexity than necessary.»

Result for the patients infected with E. coli showed similar patterns of succession; but in addition to being dominated by E. coli at the infection stage, late - stage species began appearing as early as day 7 in some patients.

This is critical because clinicians must know this rate at their institution to correctly calculate the accuracy of «rule - out» test results for each patient.

(An endoscopic video showing before - and - after results for this patient may be viewed here: https://www.youtube.com/watch?v=ajmOm06GFeA&feature=youtu.be).

«Both physical functioning and quality of life are severely affected, and while many treatments are used to relieve symptoms and try to get the disease under control, this largest set of placebo - controlled information to date clearly shows that improvement can result for patients.»

She believes that brain function, the mind and body are all part of an orchestra that should be tuned as a whole to achieve the best result for the patient.

The results for this patient are very clear: reduced pain when walking!

Immediate results for your patient are given - no tape review delay and no waiting for a report to arrive days later.

• Ranked at the top of new residents due to my constant high results for patient satisfaction and overall performance.

Not exact matches

While the new mid-stage study results from DNDi were impressive (they showed cure rates of 96 % to 97 % even for the sickest patients and those with liver scarring), more late - stage trials will be necessary before the drug is available on a large scale in the developing world.

And the results were evident in patients with a variety of genetic mutations, meaning that the medicine's market could expand substantially if Clovis wins an expanded label for Rubraca.

This increase in abnormal test results can have negative consequences for medicine in the form of extra testing, additional patient visits to clinics / hospitals, and added doctor services, all of which result in additional costs and burdens to patients or to the healthcare system and are potentially harmful.

As a result, phage therapy is now used only for the sickest patients, as a treatment of last resort.

When investors recently berated Bombardier for lack of results, Sabia took time out of a conference call to urge them to be patient.

Because this scenario showcases a slew of problems that are endemic to our modern healthcare system — from the utter lack of bacterial control in clinical settings and the associated infections that result... to a process that shuttles vulnerable patients in and out of emergency rooms for piecemeal diagnosis and treatment... to overcrowded, overburdened hospitals that still mindlessly cling to patient - management processes that haven't worked for decades.

HEART APP IMPROVES JOHNS HOPKINS» PATIENT OUTCOMES: A new cardiology - focused iPhone app is reducing readmission rates for heart attack patients, resulting in massive savings, according to a Johns Hopkins University study.

In a late - stage trial, Darzalex combined with Velcade and chemotherapy slashed patients» risk of worsening disease or death by a stunning 61 % compared with the results for Velcade and chemotherapy alone.

Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward - looking statements include, among others, the following: our ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; our ability to meet demand for our products and services; the willingness of health insurance companies and other payers to cover Cologuard and adequately reimburse us for our performance of the Cologuard test; the amount and nature of competition from other cancer screening and diagnostic products and services; the effects of the adoption, modification or repeal of any healthcare reform law, rule, order, interpretation or policy; the effects of changes in pricing, coverage and reimbursement for our products and services, including without limitation as a result of the Protecting Access to Medicare Act of 2014; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on Form results and financial condition to differ materially from those indicated in the forward - looking statements include, among others, the following: our ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; our ability to meet demand for our products and services; the willingness of health insurance companies and other payers to cover Cologuard and adequately reimburse us for our performance of the Cologuard test; the amount and nature of competition from other cancer screening and diagnostic products and services; the effects of the adoption, modification or repeal of any healthcare reform law, rule, order, interpretation or policy; the effects of changes in pricing, coverage and reimbursement for our products and services, including without limitation as a result of the Protecting Access to Medicare Act of 2014; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on Form Results of Operations sections of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on Form 10 - Q.

Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient.

In parallel, adjudication will be completed for all MACE which occurred during the study, including adjudication for certain events which, per protocol, can not be finally adjudicated until patients complete their final site visit and results are available from certain non-invasive diagnostic testing conducted during such site visits.

Shane Jackson, president and COO of LocumTenens.com, which conducted the survey, said the results are potential red flags for not only the finances of those physicians» offices, but also for their patients, who «rely on their doctor for a lot of information.»

That range was determined in March to be cost effective by the independent Institute for Clinical and Economic Review (ICER) for highest risk patients assuming the drug results in a sustained reduction in cardiovascular - related deaths.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Second, while having a «supportive» and patient dominant shareholder allowed the company to pursue long - term plays and make decisions that wouldn't pay off for years — such as the investment in the oilsands and the Southeast Asia play — such long - term goals were often pursued at the expense of short - term results.

Eighty one patients in a six - month period received hematology results that were not adequately controlled for quality.

She said that employers» increased use of high - deductible plans, one of the side - effects of the law, has resulted in patients paying more out of pocket for the drug, and that's «where you're seeing a lot of noise around EpiPen.»

«The positive efficacy results observed in the pivotal phase 3 clinical trials indicate that sarecycline can be an effective treatment option for patients with moderate to severe acne,» said Allergan R&D chief David Nicholson in a statement.

«Based on the results from these Phase 3 studies, the combination of bictegravir and FTC / TAF could represent an important advance in triple - therapy treatment for a broad range of HIV patients, and we look forward to submitting regulatory applications in the U.S. and EU this year.»

David Roman of Goldman Sachs Research shares how an Internet of Things - enabled US healthcare system could result in better outcomes for patients and efficiency gains across the healthcare space.

Join us for key insights from the CoMMpass Study, including results that patients and caregivers may find helpful for treatment decisions.

Focusing exclusively on high - potential products that align with health system priorities and patient needs, EXCITE's pre-market approach identifies opportunities for improvement while products are still in development, resulting in better technologies for patients and lower system costs, while also streamlining the subsequent adoption process.

I've owned it for the past three years with a cost average of $ 4.64 - it's the future of cancer treatment in my opinion, with brain cancer patients living 7 plus years on its lead drug and impressive results in its second drug candidate for triple negative breast cancer.

In theory, it's easier for patients, it's cheaper for healthcare systems, and the results (in early testing) seem just as good.

Say the result that comes back is for a Northwell GoHealth Urgent Care location, but the patient would prefer to go to the emergency department at their preferred hospital.

changes in government reimbursement for our services and / or new payment policies (including, for example, the expiration of the moratorium limiting the full application of the 25 Percent Rule that would reduce our Medicare payments for those patients admitted to a long term acute care hospital from a referring hospital in excess of an applicable percentage admissions threshold) may result in a reduction in net operating revenues, an increase in costs, and a reduction in profitability;

Interim results showed that a majority of the 22 patients in the two Phase 1/2 studies followed for two years or longer remained free from transfusions.

TORONTO, May 16, 2017 — An at - home sleep apnea test will be available to Ontario patients for the first time as the result of a unique MaRS program.